Evidence map›Paper›PMID 25729638›Full record

ArticleCurrent transplantation reports2015

Bioreactor Development for Lung Tissue Engineering.

Angela Panoskaltsis-Mortari

Abstract read
In one paragraph

Article in Current transplantation reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Microfluidic Systems for Neural Cell Studies.Bioengineering (Basel, Switzerland) · 2023
    Review
  3. Review
  4. Review
  5. Emerging Paradigms in Bioengineering the Lungs.Bioengineering (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Article
  8. Lung Microvascular Niche, Repair, and Engineering.Frontiers in bioengineering and biotechnology · 2020
    Review
  9. 3D bioprinting for lungs and hollow organs.Translational research : the journal of laboratory and clinical medicine · 2019
    Review
  10. Review
  11. Review
  12. Coming to terms with tissue engineering and regenerative medicine in the lung.American journal of physiology. Lung cellular and molecular physiology · 2015
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Angela Panoskaltsis-MortariDepartments of Pediatrics and Medicine; Blood and Marrow Transplant Program; Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN, 55455, U.S.A.

Funding

Overcoming Barriers to Bioengineering 3-D Human LungR01HL108627 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANOSKALTSIS-MORTARI, ANGELA, TAYLOR, DORIS A · 2011 to 2014
$3.0M
NHLBI NIH HHS R01 HL108627
6 · The paper itself

Abstract

rationaleMuch recent interest in lung bioengineering by pulmonary investigators, industry and the organ transplant field has seen a rapid growth of bioreactor development ranging from the microfluidic scale to the human-sized whole lung systems. A comprehension of the findings from these models is needed to provide the basis for further bioreactor development.

objectiveThe goal was to comprehensively review the current state of bioreactor development for the lung.

methodsA search using PubMed was done for published, peer-reviewed papers using the keywords "lung" AND "bioreactor" or "bioengineering" or "tissue engineering" or "ex vivo perfusion". MAIN

resultsMany new bioreactors ranging from the microfluidic scale to the human-sized whole lung systems have been developed by both academic and commercial entities. Microfluidic, lung-mimic and lung slice cultures have the advantages of cost-efficiency and high throughput analyses ideal for pharmaceutical and toxicity studies. Perfused/ventilated rodent whole lung systems can be adapted for mid-throughput studies of lung stem/progenitor cell development, cell behavior, understanding and treating lung injury and for preliminary work that can be translated to human lung bioengineering. Human-sized ex vivo whole lung bioreactors incorporating perfusion and ventilation are amenable to automation and have been used for whole lung decellularization and recellularization. Clinical scale ex vivo lung perfusion systems have been developed for lung preservation and reconditioning and are currently being evaluated in clinical trials.

conclusionsSignificant advances in bioreactors for lung engineering have been made at both the microfluidic and the macro scale. The most advanced are closed systems that incorporate pressure-controlled perfusion and ventilation and are amenable to automation. Ex vivo lung perfusion systems have advanced to clinical trials for lung preservation and reconditioning. The biggest challenges that lie ahead for lung bioengineering can only be overcome by future advances in technology that solve the problems of cell production and tissue incorporation.

Indexed as

BioengineeringBioreactorLungTissue Engineering

Identifiers

PMID25729638
PMCPMC4339073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.